发明名称 |
TRIPHASIC ORAL CONTRACEPTIVE |
摘要 |
A method of contraception in which an estrogen and a progestogen are administered daily in a three phase sequence for 21 days is disclosed. In the first phase a combination of an estrogen and a progestogen in a low but contraceptively effective daily dosage corresponding in estrogenic activity to 23-28 mug of 17alpha-ethinylestradiol and in progestogenic activity to 0.065-0.75 mg of norethindrone is administered for 5-8 days; followed by the administering of the same dosage of estrogen and a progestogen corresponding in progestogenic activity to 0.25-1.0 mg of norethindrone for 7-11 days; followed by the administering of the same dosage of estrogen and a progestogen corresponding in progestogenic activity to 0.35-2.0 mg of norethindrone for 3-7 days; followed by 4-8 days without administering either an estrogen or a progestogen.
|
申请公布号 |
HU229251(B1) |
申请公布日期 |
2013.10.28 |
申请号 |
HU20010004680 |
申请日期 |
1999.12.08 |
申请人 |
ORTHO-MCNEIL PHARMACEUTICAL, INC. |
发明人 |
SHANGOLD, GARY;RUBIN, ARKADY;UPMALIS, DAVID |
分类号 |
A61K31/565;A61K31/567;A61K31/569;A61K31/57;A61P15/18 |
主分类号 |
A61K31/565 |
代理机构 |
|
代理人 |
|
主权项 |
|
地址 |
|